Detailed Narrative
FY25 Performance Overview
Nath Bio-Genes reported a resilient FY25 with total revenue reaching INR362.30 crores, showing a steady increase (around 9% YoY) over FY24. Gross margins remained strong at over 52%, while EBITDA grew by almost 4% to INR52 crores. Net profit (PAT) saw a more significant rise of 13.3% to INR41.6 crores, reflecting improved profitability.
Diversification Strategy & NCP Growth
The company's strategic focus on diversification proved successful, with the non-cotton, non-paddy (NCP) portfolio emerging as a strong growth pillar. The NCP segment's contribution to revenue increased to 48% in FY25 from 43% last year, with revenue growing 38% to INR171 crores from INR140 crores in FY24. This highlights the success of reducing reliance on traditional crops.
Product Performance & Market Leadership
Flagship cotton hybrids, Nath Sanket and Jumbo, continued to lead with solid growth. In paddy, the strategy of focusing on hybridization resulted in hybrid paddy contributing 38% in value and 19% in volume. Bajra, led by Super-27, grew 8.77%, maize by 47%, and the vegetable segment saw significant value growth of 60.45% and volume growth of 76.71%. The plant nutrition segment also performed well, growing 23.53%.
International Expansion & Joint Ventures
Nath Bio-Genes made tangible progress on the international front. In Uzbekistan, a joint venture with 90% shareholding is progressing well, with marketing underway and large areas secured for cotton production, expected to yield good results next year. In the Philippines, the company has received approval for its BT cotton and is optimistic about commercial sales to the government.
Financial Health & Working Capital Management
The company demonstrated improved financial prudence, with debtor days reducing to 89 days from 103 days. A positive cash flow from operations of INR26.8 crores was achieved, and the bank balance stood at INR87.6 crores as of March 31, 2025. The credit rating was upgraded by 2 notches to BBB+, endorsing its healthy financial outlook.
R&D and Innovation Focus
Nath Bio-Genes continues to invest significantly in research and development, spending around INR10-12 crores annually, representing 4-5% of the top line. This investment is crucial for strengthening germplasm, creating high-yielding hybrids, and developing products with better resistance against diseases and pests, ensuring sustained market leadership.
Future Outlook & Growth Targets
Management aims for a 15% revenue growth this year (FY26) and targets INR500 crores in sales within the next one to two years, with a long-term aspiration of INR1,000 crores. They also expect to improve EBITDA and PBT margins by 2-3 basis points. Advanced bookings for FY26 increased by 63% to INR151.21 crores, indicating strong market acceptance.